ECSP066718A - DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE - Google Patents

DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE

Info

Publication number
ECSP066718A
ECSP066718A EC2006006718A ECSP066718A ECSP066718A EC SP066718 A ECSP066718 A EC SP066718A EC 2006006718 A EC2006006718 A EC 2006006718A EC SP066718 A ECSP066718 A EC SP066718A EC SP066718 A ECSP066718 A EC SP066718A
Authority
EC
Ecuador
Prior art keywords
treatment
pirazolo
pirimidin
amina
derivatives
Prior art date
Application number
EC2006006718A
Other languages
Spanish (es)
Inventor
Pascal Furet
Keiichi Masuya
Guido Bold
Andreas Floersheimer
Patricia Imbach
Joseph Schoepfer
Georg Martiny-Baron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066718A publication Critical patent/ECSP066718A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere al uso de compuestos de pirazolo[1,5-a]pirimidin-7-il-amina y sales de los mismos, en el tratamiento de enfermedades dependientes de quinasa, y para la fabricación de preparaciones farmacéuticas para el tratamiento de estas enfermedades, a compuestos novedosos de pirazolo[1,5-a]pirimidin-7-il-amina, y a un proceso para la preparación de los compuestos novedosos de pirazolo[1,5-a]pirimidin-7-il-amina.The invention relates to the use of pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds and salts thereof, in the treatment of kinase-dependent diseases, and for the manufacture of pharmaceutical preparations for the treatment of these diseases, to novel pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds, and to a process for the preparation of novel pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds.

EC2006006718A 2004-01-22 2006-07-21 DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE ECSP066718A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53822004P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
ECSP066718A true ECSP066718A (en) 2006-10-31

Family

ID=34807167

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006718A ECSP066718A (en) 2004-01-22 2006-07-21 DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE

Country Status (17)

Country Link
EP (1) EP1708710A1 (en)
JP (1) JP2007519662A (en)
KR (1) KR20070009546A (en)
CN (1) CN1909908A (en)
AR (1) AR049769A1 (en)
AU (1) AU2005205915B2 (en)
BR (1) BRPI0507071A (en)
CA (1) CA2552885A1 (en)
EC (1) ECSP066718A (en)
IL (1) IL176737A0 (en)
MA (1) MA28400B1 (en)
NO (1) NO20063758L (en)
PE (1) PE20051089A1 (en)
RU (1) RU2006130003A (en)
TN (1) TNSN06226A1 (en)
TW (1) TW200528103A (en)
WO (1) WO2005070431A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
BRPI0616985B1 (en) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. PIRAZOLE[1,5-A]PYRIMIDINE COMPOUND, E, USE OF A COMPOUND
ES2403206T3 (en) 2005-12-23 2013-05-16 Ariad Pharmaceuticals, Inc. Heteroaryl bicyclic compounds
JP2009529054A (en) * 2006-03-08 2009-08-13 ノバルティス アクチエンゲゼルシャフト Use of pyrazolo [1,5A] pyrimidin-7-ylamine derivatives in the treatment of neurological disorders
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
GB0606805D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic compounds
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
CN101516888A (en) * 2006-09-28 2009-08-26 诺瓦提斯公司 Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
BRPI0717564A2 (en) 2006-09-29 2013-10-22 Novartis Ag PIRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
EP1918291A1 (en) * 2006-10-30 2008-05-07 Novartis AG 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
JP5198562B2 (en) * 2007-06-07 2013-05-15 メルク・シャープ・アンド・ドーム・コーポレーション Synthesis of substituted-3-aminopyrazoles
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
UY33227A (en) * 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
BR112012029405B1 (en) 2010-05-20 2021-01-05 Array Biopharma Inc. macrocyclic compounds such as trk kinase inhibitors, pharmaceutical composition, use of a compound of formula i or a pharmaceutically acceptable salt thereof, process for the preparation of a compound
KR101856266B1 (en) * 2010-08-09 2018-05-09 가부시키가이샤 에누비 켄코우겡큐쇼 INHIBITOR OF CASEIN KINASE 1δ AND CASEIN KINASE 1ε
WO2012023143A1 (en) 2010-08-19 2012-02-23 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
KR101404151B1 (en) * 2011-11-25 2014-06-05 가톨릭대학교 산학협력단 Composition for preventing and treating ocular diseases
CN105906630B (en) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN106588893A (en) * 2016-12-01 2017-04-26 北京万全德众医药生物技术有限公司 Preparation of vilazodone double oxide
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (en) 2017-01-18 2022-04-26 阿雷生物药品公司 Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP7377207B2 (en) 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー GCN2 inhibitors and their uses
KR20200116481A (en) * 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 GCN2 inhibitors and uses thereof
ES2922314T3 (en) 2018-09-10 2022-09-13 Array Biopharma Inc Fused Heterocyclic Compounds as RET Kinase Inhibitors
CN109836428A (en) * 2019-02-27 2019-06-04 华东师范大学 Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity
EP3996736A4 (en) * 2019-07-10 2023-05-24 Musc Foundation for Research Development ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY
PH12022551282A1 (en) 2019-11-25 2023-11-29 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
WO2023154282A1 (en) * 2022-02-08 2023-08-17 Theras, Inc. Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
CN114751910B (en) * 2022-05-17 2023-02-24 重庆文理学院 Compound capable of inducing cell megalophage death and preparation method and application thereof
CN117843642A (en) * 2022-10-09 2024-04-09 麦科萨药业(苏州)有限公司 A bifunctional compound and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (en) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
JP3163413B2 (en) * 1994-06-21 2001-05-08 株式会社大塚製薬工場 Painkillers
EP0714898B1 (en) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
WO1998010590A1 (en) * 1996-09-02 1998-03-12 Sony Corporation Device and method for transmitting video signal
CN1694705A (en) * 2002-09-04 2005-11-09 先灵公司 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003268385B2 (en) * 2002-09-04 2006-12-21 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
CA2552885A1 (en) 2005-08-04
AU2005205915A1 (en) 2005-08-04
WO2005070431A1 (en) 2005-08-04
PE20051089A1 (en) 2006-01-25
KR20070009546A (en) 2007-01-18
JP2007519662A (en) 2007-07-19
NO20063758L (en) 2006-10-23
AU2005205915B2 (en) 2009-05-21
EP1708710A1 (en) 2006-10-11
TW200528103A (en) 2005-09-01
BRPI0507071A (en) 2007-06-19
RU2006130003A (en) 2008-04-10
MA28400B1 (en) 2007-01-02
TNSN06226A1 (en) 2007-12-03
AR049769A1 (en) 2006-09-06
CN1909908A (en) 2007-02-07
IL176737A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
ECSP066718A (en) DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
MX2007005644A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors.
DE60323090D1 (en) 1H-IMIDAZOÄ4,5-CÜCHINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES
CR8171A (en) PIRROLO DERIVATIVES [3,4-C] PYRAZOL ASSETS AS QUINASA INHIBITORS
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
ATE400573T1 (en) 1H-IMIDAZOCINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
BRPI0519567A2 (en) tricyclic heterocycles, their manufacture and use as pharmaceutical agents
PE20080548A1 (en) DERIVATIVES OF [4,5 '] BIPYRIMIDINYL-6,4'-DIAMINE AS PROTEIN KINASE INHIBITORS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
CL2004000889A1 (en) COMPOUNDS DERIVED FROM PIRAZOLO [4,3-d] PYRIMIDINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HYPERTENSION.
PA8637601A1 (en) MODULATING COMPOUNDS OF C-KIT ACTIVITY AND USES OF THE SAME
NO20071875L (en) Bicyclic amides as kinase inhibitors
UY27222A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
CY1111921T1 (en) 7- [2- [4- (6-Fluoro-3-methyl-1,2-benzisoxazol-5-yl) -1-piperazinyl] ethyl] -2- (1-propynyl) -7H-pyrazolo- [4, 3-e] - [1,2,4] -Triazolo [1,5-c] PYRIMIDIN-5-AMINE
CY1110666T1 (en) PYRAZOLOPYRIMIDINES SUITABLE FOR CANCER DISEASE TREATMENT
ATE432281T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
GT200500020A (en) DERIVATIVES OF 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS.
EA200600833A1 (en) TIAZOLIDINONONY, THEIR RECEIVING AND APPLICATION AS PHARMACEUTICAL AGENTS
ATE496899T1 (en) TETRAHYDRO- AND DIHYDROQUINAZOLINONES
DE602005014087D1 (en) 7H-PYRROLOPYRIMIDINDERIVATE